Novartis India: From Pilot to Global Powerhouse
Novartis has transformed its India operations into the single largest component of its global capability network. Today, nearly two-thirds of the company’s GCC workforce is based in India, with close to 9,000 professionals in Hyderabad alone.
What started in 2001 as a 20-person team in Mumbai, focused on basic drug development and data support, has evolved over 25 years into Novartis’s primary R&D and operations hub globally.
-
Evolution from Modest Beginnings to Strategic Global Hub
The initial India setup was designed to test feasibility. Over time, as confidence in India’s capabilities grew, Novartis systematically transitioned complex, mission-critical work to Hyderabad. This marked a deliberate move away from cost arbitrage toward capability-driven global integration.
“In 2001, we started with a team of just 20 people in Mumbai… it was about testing whether the model worked. These were very tactical roles.”
– Ganpat Anchaliya, Site Head, Novartis Corporate Centre, Hyderabad
-
A Comprehensive End-to-End Functional Footprint
Today, the Hyderabad GCC mirrors the breadth and depth of Novartis’s global operations. Its scope spans:
- Biomedical research and wet labs
- Clinical development and drug safety
- Enterprise finance and commercial analytics
- Supply chain, procurement, HR, and compliance
Roughly 3,000 professionals are directly involved in drug development, with significant ownership across quality, regulatory, and advanced analytics functions. Hyderabad is no longer a downstream executor, it is embedded across the entire product lifecycle.
-
Talent and Capability as the True Differentiator
While cost efficiencies triggered early expansion, Novartis’s sustained success in India is rooted in talent depth and specialized capability. The establishment of wet lab operations in Genome Valley marked a critical inflection point. Regulatory approvals enabled Novartis to scale high-value scientific work locally, something previously difficult to achieve in India.
“Every molecule that turns into medicine for Novartis today has imprints from Hyderabad.”
– Ganpat Anchaliya, Site Head, Novartis Corporate Centre, Hyderabad
Approximately 350 scientists now work in formulation development, analytical research, and stability studies—generating data and IP that directly feed global drug filings.
From Cost Arbitrage to Capability Leadership
Inside the Operations: Scale with Substance
- Drug Development: ~3,000 specialists designing clinical protocols and managing global trial execution.
- Pharmacovigilance: Nearly 90% of Novartis’s global drug safety operations are run from Hyderabad.
- Biomedical Research: A 200-member PhD-led unit focused on early-stage, pre-clinical research.
Novartis accelerated its India expansion during the 2009-2012 period amid global cost pressures and patent expirations. But the company’s leadership was clear-eyed about sustainability.
“After the first year or two, cost arbitrage disappears. What stays is capability and skill.”
– Ganpat Anchaliya, Site Head, Novartis Corporate Centre, Hyderabad
Today, Hyderabad hosts 70-80% of Novartis’s global quality professionals and an 800-strong finance organization. With 95% functional coverage, the GCC operates with near autonomy, effectively a parallel headquarters.
Strengthening India’s Life Sciences Ecosystem
Beyond enterprise impact, Novartis plays a pivotal role as an anchor institution within Hyderabad’s life sciences ecosystem. By training thousands of scientists and quality professionals to global standards, it strengthens India’s broader talent infrastructure, benefiting the entire pharma ecosystem.
This ecosystem credibility is critical when global pharma companies evaluate India for advanced R&D and innovation investments.
Impact for Global Pharma & the Road Ahead
- 25 years of compounded capability creates a structural advantage competitors cannot replicate quickly.
- 90% pharmacovigilance ownership reflects deep regulatory trust and operational excellence.
- 95% functional coverage enables speed, autonomy, and resilience.
- Wet labs and core R&D firmly places India inside the innovation engine, not the periphery.
The message is unambiguous: India can handle the most sophisticated pharmaceutical work globally, not just manufacturing or generics.
If Big Pharma’s investments in Hyderabad accelerate, Novartis has set the blueprint. If they don’t, Novartis has built something genuinely hard to replicate, and that advantage will compound for decades.
Ask an Expert
